Global Anti-Obesity Prescription Market Growth 2023-2029

Global Anti-Obesity Prescription Market Growth 2023-2029

Obesity is a public health problem. Obesity is a genetic and chronic metabolic disease involving accumulation of excessive or abnormal fat in the body. It contributes to risk of chronic conditions such as cancer, hypertension, cardiovascular diseases, diabetics, obstructive sleep apnea, ventilatory failure, renal failure and asthma. According to a World Health Organization (WHO) report published in 2014, around 3.4 million adults in the world die each year due to obesity related issues. Increasing prevalence of obesity among children and adults is posing a threat and developing nations. Effective intervention strategies such as increased physical activity, behavioral and dietary changes are commonly used to control and prevent obesity. Obesity has a major impact on population longevity and health related expense.

LPI (LP Information)' newest research report, the “Anti-Obesity Prescription Industry Forecast” looks at past sales and reviews total world Anti-Obesity Prescription sales in 2022, providing a comprehensive analysis by region and market sector of projected Anti-Obesity Prescription sales for 2023 through 2029. With Anti-Obesity Prescription sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-Obesity Prescription industry.

This Insight Report provides a comprehensive analysis of the global Anti-Obesity Prescription landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-Obesity Prescription portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Anti-Obesity Prescription market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-Obesity Prescription and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-Obesity Prescription.

The global Anti-Obesity Prescription market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

There is increased use of anti-obesity prescription due to increasing obesity endemic. Sedentary lifestyle and junk food habits, increasing healthcare expenditure and rise in aging population are some of the key factors driving the growth for global anti-obesity prescription market. In addition, increasing healthcare awareness is also fuelling the growth of the global anti-obesity prescription market. However, side effects of anti-obesity drugs, high drug development cost and strict regulatory framework are some of the major factors restraining the growth for the global anti-obesity prescription market.

This report presents a comprehensive overview, market shares, and growth opportunities of Anti-Obesity Prescription market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Bupropion and Naltrexone
Orlistat
Lorcaserin
Phentermine and Topiramate
Liraglutide

Segmentation by application
Hospital Pharmacies
Retail Pharmacies
E-Commerce

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Zydus Cadila
Akrimax Pharmaceuticals
Zealand Pharma
Arrowhead Research
Arena Pharmaceuticals
Compellis Pharmaceuticals
Yungjin Pharm
Alpex Pharma
Bridge BioResearch

Key Questions Addressed in this Report

What is the 10-year outlook for the global Anti-Obesity Prescription market?

What factors are driving Anti-Obesity Prescription market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Anti-Obesity Prescription market opportunities vary by end market size?

How does Anti-Obesity Prescription break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.